Search Results for "Antidepressants"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Antidepressants. Results 161 to 170 of 185 total matches.
Transdermal Methylphenidates (Daytrana) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006 (Issue 1237)
the metabolism and might
increase the toxicity of tricyclic antidepressants
(TCAs) and selective serotonin ...
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Nabilone (Cesamet) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
when used with other drugs, such as tricyclic antidepressants.
AVAILABLE USUAL ADULT
DRUG ...
Nabilone, an oral synthetic cannabinoid similar to delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, has recently been reintroduced to the US market (Cesamet - Valeant) after a 17-year absence. The previous manufacturer discontinued marketing of the drug for commercial reasons. Nabilone is classified as a Schedule II controlled substance.
Milnacipran (Savella) for Fibromyalgia
The Medical Letter on Drugs and Therapeutics • Jun 15, 2009 (Issue 1314)
have included analgesics,
muscle relaxants, anticonvulsants, and antidepressants with pain-relieving properties ...
Milnacipran (Savella - Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gammaaminobutyric acid (GABA) analog also approved for treatment of diabetic neuropathy, post-herpetic neuralgia and epilepsy, and duloxetine, an SNRI also approved for treatment of depression, diabetic neuropathy and generalized anxiety disorder.
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
The Medical Letter on Drugs and Therapeutics • Oct 10, 2016 (Issue 1505)
(MAO) inhibitors, tricyclic antidepressants,
or other drugs that prolong the QT interval8 could ...
The FDA has approved a fixed-dose combination of
the long-acting anticholinergic glycopyrrolate and
the long-acting beta2-adrenergic agonist (LABA)
formoterol (Bevespi Aerosphere – AstraZeneca) for
long-term maintenance treatment of patients with
chronic obstructive pulmonary disease (COPD).
Glycopyrrolate/formoterol is the fourth long-acting
anticholinergic/LABA combination to be approved in
the US, but the first to become available in a metered-dose
inhaler. Glycopyrrolate/indacaterol (Utibron
Neohaler), umeclidinium/vilanterol (Anoro Ellipta),
and tiotropium/olodaterol (Stiolto...
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
) or a tricyclic antidepressant
could increase the risk of cardiovascular adverse
effects. Coadministration ...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):41-3 doi:10.58347/tml.2024.1698a | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
.5 Antidepressant drugs such as selective
serotonin reuptake inhibitors (SSRIs) or bupropion ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Ropinirole for Restless Legs Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005 (Issue 1214)
, antipsychotics, antidepressants) may
cause additive sedative effects when taken with
ropinirole.
DOSAGE ...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Trelegy Ellipta - A Three-Drug Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
inhibitors or tricyclic antidepressants can result
in additive cardiovascular effects. Beta blockers ...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the long-acting
beta2-agonist (LABA) vilanterol. It is available as a dry
powder inhaler for once-daily maintenance treatment
of COPD and to reduce COPD exacerbations in patients
with a history of exacerbations. Trelegy Ellipta is
the first three-drug inhaler for treatment of COPD to
become available in the US.
Formoterol (Perforomist) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007 (Issue 1274)
be used
cautiously with formoterol. MAO inhibitors and tricyclic
antidepressants may have additive ...
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
Cost3 Some Adverse Effects Comments
Tricyclic Antidepressant
Doxepin – generic
Silenor (Pernix ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction